IP Library Granted Patent US 7,323,167
Granted Patent B2
US 7,323,167 · App. 10/757,843 · Granted Jan 29, 2008

Method of treatment with modified arginine deiminase

Assignee: Polaris Group
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,323,167
App. No.
10/757,843
Granted
Jan 29, 2008
Kind
B2
Abstract

The present invention is directed to arginine deiminase modified with polyethylene glycol, to methods of treating cancer, and to methods of treating and/or inhibiting metastasis.

Claims (17)

1. A method of enhancing the circulating half life of arginine deiminase comprising modifying said arginine deiminase by covalently bonding said arginine deiminase via a linking group to polyethylene glycol,

wherein the arginine deiminase is derived from a microorganism of the genus selected from the group consisting of: Steptococcus, Borrelia, Qiardia, Clostridium, Enterococcus, Lactobacillus , and Bacillus;

wherein the polyethylene glycol has a total weight average molecular weight of from about 1,000 to about 40,000, and

wherein the linking group is selected from the group consisting of a succinimide group, an amide group, an imide group, a carbarmate group, an ester group, an epoxy group, a carboxyl group, a hydroxyl group, a carbohydrate, a tyrosine group, a cysteine group, a histidine group and combinations thereof.

2. A method of treating a tumor in a patient comprising administering to said patient a compound comprising arginine deiminase covalently bonded via a linking group to polyethylene glycol,

wherein the arginine deiminase is derived from a microorganism of the genus selected from the group consisting of: Steptococcus, Borrelia, Qiardia, Clostridium, Enterococcus, Lactobacillus , and Bacillus;

wherein the polyethylene glycol has a total weight average molecular weight of from about 1,000 to about 40,000, and

wherein the linking group is selected from the group consisting of a succinimide group, an amide group, an imide group, a carbamate group, an ester group, an epoxy group, a carboxyl group, a hydroxyl group, a carbohydrate, a tyrosine group, a cysteine group, a histidine group and combinations thereof.

3. The method of claim 2 , wherein said tumor is a melanoma.

4. The method of claim 3 , wherein said polyethylene glycol has a total weight average molecular weight of about 20,000.

5. The method of claim 3 , wherein said linking group is a succinimide group.

6. The method of claim 5 , wherein said succinimide group is succinimidyl succinate, succinimidyl propionate, succinimidyl carboxymethylate, succinimidyl succinamide, N-hydroxy succinimide or combinations thereof.

7. The method of claim 2 , wherein said tumor is a hepatoma.

8. The method of claim 7 , wherein said polyethylene glycol has a total weight average molecular weight of about 20,000.

9. The method of claim 7 , wherein said linking group is a succinimide group.

10. The method of claim 9 , wherein said succinimide group is succinimidyl succinate, succinimidyl propionate, succinimidyl carboxymethylate, succinimidyl succinamide, N-hydroxy succinimide or combinations thereof.

11. The method of claim 2 , wherein said tumor is a sarcoma.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2007
From: PHOENIX PHARMACOLOGICS, INC.
To: POLARIS GROUP
Reel/Frame 019988/0963 →
Continuity (4)
Division 0972354600 · Nov 28, 2000
Continuation In Part 0902380900 · Feb 13, 1998
Provisional Application 6004620000 · May 12, 1997
Related Publication 20050129706A1 · Jun 16, 2005